SCHEMBL6703391

SCHEMBL6703391

CC(C)(C)OC(=O)CNC(=O)C1OC(=O)C=C1c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 2/20 0.40
GABRA5 P31644 1/20 0.37
LMNA P02545 2/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
NCOA1 Q15788 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
MAPT P10636 3/20 0.35
POLB P06746 2/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6704662 0.80 MIF (0.38) LMNAHPGDKDM4EALDH1A1HRH3
SCHEMBL6703580 0.69 GAA (0.49) LMNAHPGDKDM4EMEN1ALDH1A1
SCHEMBL6084716 0.66 PTPRC (0.62) PTPRCLMNAKDM4ESMN1; SMN2POLB
SCHEMBL9080144 0.66 LIPG (0.46) PTPRCLMNAHPGDMEN1ALDH1A1
SCHEMBL303932 0.64 PKM (0.46) PTPRCLMNAHPGDMEN1ALDH1A1
SCHEMBL7469076 0.64 PTPRC (0.49) PTPRCGABRA5KDM4EALDH1A1MAPT
SCHEMBL9551634 0.64 CRHBP (0.60) LMNAHPGDKDM4EMEN1ALDH1A1
SCHEMBL6085598 0.64 PTPRC (0.49) PTPRCKDM4EALDH1A1POLBL3MBTL1
SCHEMBL8562534 0.64 HPGD (0.65) PTPRCHPGDHTTKMT2ASMN1; SMN2
SCHEMBL8564576 0.64 HPGD (0.65) PTPRCHPGDHTTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102488-A1 Butenolide and pentenolide derivatives as kinase inhibitors MORPHOCHEM AG (DE) 2004-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102488-A1 Butenolide and pentenolide derivatives as kinase inhibitors MAP3K20, MAP3K21, MAP3K1 PTPRC 890/4885GABRA5 967/4885LMNA 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.